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The global burden of cardiovascular diseases in
2010 and changes between 1990 and 2010
Worldwide, the cardiovascular diseases (CVDs) contributing
most to the total global burden of disease in 2010 were
ischemic heart disease (5.2% of all disability-adjusted life
years [DALYs] lost) and stroke (4.1% of all DALYs). The
other major CVDs were hypertensive heart disease, cardio-
myopathies, rheumatic heart disease, atrial ﬁbrillation, aortic
aneurysm, peripheral vascular disease, and endocarditis. The
highest per capita CVD burden fell upon the Eastern Europe
and Central Asia regions (Fig. 1). In the large populations of
the South Asia andNorth Africa andMiddle East regions, the
absolute burden of CVDs is high and more often affects
young, working-age adults. CVD burden declined sharply in
the world’s high-income regions between 1990 and 2010
(Fig. 2). For both stroke and ischemic heart disease, global
age-standardized mortality has decreased, but population
growth and aging have increased both the absolute number
of CVD deaths and survivors suffering with the late effects of
stroke or ischemic heart disease [1,2]. About two thirds of
new strokes and more than 70% of stroke burden affect
people younger than 75 years of age [2]. Even after adjusting
for age, the atrial ﬁbrillation prevalence and incidence
increased between 1990 and 2010, and atrial ﬁbrillation
mortality about doubled over the same interval [3]. About
200 million prevalent peripheral artery disease cases were
estimated for 2010: about 70% of them living in low- or
middle-income countries and 55 million of them in the
South Asia region [4].and Michael A. Wiener
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During 1990-2010, burden due to human immunodeﬁ-
ciency virus (HIV) increased more than any other single
cause. Most noncommunicable diseases decreased. When
viewed by proportional change in burden between 1990
and 2010, the 2 CVDs that are among the world’s leading
causes of death and disability—ischemic heart disease and
stroke—both increased in burden (percent increase in
absolute numbers of DALYs [Fig. 3]). The biggest relative
increases among the CVDs were in atrial ﬁbrillation and
peripheral vascular disease burden. In keeping with the
International Classiﬁcation of Diseases system, heart failure
was not designated as an underlying cause of disease in this
analysis. Heart failure burden was captured indirectly as a
sequela of several underlying diseases (including CVDs like
ischemic heart disease, hypertensive heart disease, cardio-
myopathies, and rheumatic heart disease).GLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16CVD burden attributable to risk factors:
Similarities and difference by world region
It comes as no surprise that classic risk factors responsible
for global CVD burden—dietary risks, high blood pressure,
and tobacco smoking—were leading risk factors across all
world regions (Fig. 4). Tobacco smoking was ranked
comparatively lower as a CVD risk factor in Australasia,
Western Europe, and North America, likely due to both
aggressive tobacco control measures and shifts in societal
attitudes toward tobacco use in recent decades. Elsewhere,
in some of the world’s most populous regions like East Asia
and Southeast Asia, tobacco is the third leading risk factor
behind dietary risks and high blood pressure. Alcohol use
ranked as the ﬁfth leading cause of CVD burden in Eastern
Europe (likely due to its association there with non-
myocardial infarction ischemic heart disease and stroke,
and possibly because acute alcoholic deaths were coded as
cardiovascular deaths), while alcohol ranked no higher
than tenth in all other regions. Ambient (outdoor) partic-
ulate matter pollution ranked particularly high (fourth) as a
risk factor for CVD in East Asia. Household air pollution
ranked high as a cause of CVD burden (third) in South Asia
and Sub-Saharan Africa. High body mass index ranked
third as a CVD risk factor not only in the Australasia, North
America, European, and Central Asia regions, but also in
Latin American/Caribbean and North Africa/Middle East.
Demographic drivers of regional CVD burden
Aging of the population has driven up CVD despite
decreased age-standardized rates in many regions. It is well
known that the populations of high-income regions, Eastern
Europe, and Central Europe are aging, with 10% or more of
the population aged >65 years (Fig. 5). In 2 regions with a
median life expectancy of >70 years—East Asia and Latin
American/Caribbean—between 5% and 10% of the popu-
lation is65 years of age, and these regions will experience a
growing per capita burden of CVD. The combination of a
young population and an average life expectancy of >70
years of age in North Africa/Middle East may lead to a
growing epidemic of CVDs in coming decades in that region.
CVD prevention and control: Do health systems
have the capacity to respond?
Even in regions with declining age-standardized CVD rates,
the absolute burden of CVD is on the increase due to longer
life expectancy and population growth. In low- and middle-
income countries, CVD risk factors are often identiﬁed late
in disease progression, and patients often must bear acute
care and prevention costs out-of-pocket, which can be3
FIGURE 1. Age standardized cardiovascular disease disability-adjusted life years (DALYs) lost per 100,000, 2010.
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4impoverishing for the household [5]. Health systems in the
low- andmiddle-income countries with highCVDburden are
challenged by the signiﬁcant investments required to
adequately prevent and treat CVD [6]. There are numerous
measures of current national health systemcapacity, including
proportion of national income devoted to health care, per
capita health care spending, and number of hospital beds and
clinics. For the Global CVD Atlas, we present a simple mea-
sure of health system capacity: medical professionals (physi-
cians, nurses, and midwives) per 10,000 people (Fig. 6).
Though even this indicator is not a direct measure of coun-
tries’ capacity for or quality of prevention and treatment, there
are substantial differences in health care provider capacity
among regions. In South Asia and East Asia, the number of
nurses and midwives is roughly the same as the number ofphysicians. Numerous countries increase the health system’s
reach by engaging the efforts of nonprofessional, lay health
workers, who facilitate health education, screening, moni-
toring, and adherence programs [7]. Multiple approaches to
improving health system capacity, including health insurance
schemes, essential medicines and quality improvement pro-
grams, and programs aiming to improve the contribution of
private sector capacity, have the potential to improve CVD
prevention and control in lower-resourced regions [8].
Global CVD surveillance: Past and present
Reliable surveillance data are a necessary component of
assessing population health and prioritizing prevention and
control efforts. Systematic surveillance began with regis-
tering births and deaths, later progressing to cause-speciﬁcGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16
FIGURE 2. Change in age standardized cardiovascular disease disability-adjusted life years (DALYs) lost per
100,000, 2010.
gATLASjdeaths (Table 1). Population demographic, risk factor, and
prevalence surveys and nonfatal event registration were
added to mortality registration, but on a national scale,
these surveillance methods were often pursued indepen-
dently. It was integration of upstream characteristics and
downstream events in landmark, population-based, car-
diovascular disease cohort studies that led to the devel-
opment of risk factor epidemiology. The Framingham
Study ﬁrst, then the World Health Organization (WHO)
MONICA (monitoring trends and determinants in cardio-
vascular disease) Study (as well as the Atherosclerosis in
Communities [ARIC] Study and Rochester Epidemiology
Study in the United States) developed advanced and
standardized surveillance methods aimed at capturing all
CVD events in large, deﬁned, subnational populations thatGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16could be translated to changes in CVD event rates over time
[9]. Until the 1990s, almost all comprehensive surveillance
was pursued in North America, Australasia, and Europe—
for example, in MONICA, China was the only country
outside of these regions to participate. In addition, while a
number of countries have a broad range of CVD surveil-
lance methods, few, even among high-income countries,
have achieved complete linkage of community, outpatient,
inpatient, and mortality data registries. In many low-
resource regions, national all-cause and cause-speciﬁc
deaths registration remains incomplete (Fig. 7).
The future of global CVD surveillance
Recent efforts in CVD surveillance have focused on the cre-
ation of comprehensive and comparable population-level5
FIGURE 3. Cardiovascular diseases in comparison with other leading causes of loss of disability-adjusted life years
(DALYs), global percent change, 1990-2010.
FIGURE 4. Risk factors for cardiovascular and circulatory diseases, ranked by disability-adjusted life years (DALYs)
attributed to each risk factor.
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FIGURE 5. Median life expectancy (years) and percent of population aged 65
years or older, by world region, 2010.
FIGURE 6. Median medical professionals per 10,000 population by world
region, 2010.
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data about cardiovascular diseases. One example is the
Global Burden of Disease (GBD) 2010 study, a systematic
effort to quantify the comparative magnitude of death and
disability in 187 countries by age and sex for the years 1990-
2010 [10]. GBD 2010 developed uniform methods for
modeling cause-speciﬁc mortality and disease prevalence
across 291 diseases and 1160 health conditions, including
10 cardiovascular diseases and more than 50 cardiovascular
health states. This kind of large-scale effort involved a
network of hundreds of clinical and public health scientists
in more than 50 countries.
Spurred by GBD 2010, efforts continue to improve
measurement of the global burden of disease. In 2013, the
Global Burden Study will begin releasing estimates annually.
In addition, there will be increased efforts tomeasure disease
burden at the subnational level. Future estimates will also
include the tracking of disease-speciﬁc health expenditures
by country. Increased sharing of administrative data among
countries will lead to a global collection of hospital data and
surgical procedures. This will contribute to an increasingly
integrated framework for understanding the changing
contribution of health care to population health.
Large meta-analytic efforts like GBD would not be
possible without ongoing, high-quality surveillance across
many countries. The WHO STEPwise approach to Surveil-
lance program has made standardized survey instruments
available in many countries where little was previously know
about cardiovascular disease burden [7]. Increasingly,
developing low-income regions conduct cardiovascular dis-
ease epidemiology studies, as with the Dhulikel Heart Study
in Nepal, and work on stroke in urban and rural Tanzania
[11,12]. Large multinational efforts led by the Population
Health Research Institute at McMaster University have
continued to expand on the work of past epidemiology
studies, producing landmark studies such as InterHeart,
InterStroke, and PURE [13e15]. In high-income countries,
traditional epidemiologic methods such as survey, registry,
and case-control studies are increasingly being supplemented
with large-scale data linkage studies. These effortsmake use of
large administrative data sets and unique identiﬁers to track
hospital and pharmacy care among patients with key car-
diovascular conditions [16,17].
An ideal system for cardiovascular surveillance does
not yet exist, but it is useful to consider the attributes that
such a system might have. To remain patient focused, it
will need to collect data across multiple points of care
rather than just hospital discharge. To be useful at the
level of health systems, it will necessarily track efﬁciency
by collecting information on cost inputs and health out-
puts. It will allow the measurement of the effective
coverage of interventions. Effective coverage has been
deﬁned as the proportion with a health condition that
receives the expected beneﬁt of an intervention [18]. A
ﬂexible surveillance system will be able to rapidly adopt
new metrics and indicators. Most importantly, an ideal
system for cardiovascular surveillance will need to be
population focused, which will require investment inGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16surveys that sample at the levels of schools, employers,
institutions, and households.
There remain signiﬁcant challenges to CVD surveillance.
Data sources remain sparse in some regions of the world,
notably sub-Saharan Africa and small countries in Oceania.
Less developed systems require ongoing investments if they
are to improve beyond more than limited efforts at tracking
mortality. It remains challenging to collect the full range of
behavioral and environmental risk factors that lead to car-
diovascular diseases. Signiﬁcant variation exists in the way
that data are collected on even the best know exposures, such
as tobacco. Biomarkers are still only measured in a handful of
WHO STEPs surveys, and additional resources will be
necessary to expand this important component of surveil-
lance. Additionally, some diseases remain extremely difﬁcult7
TABLE 1. Components of cardiovascular disease surveillance
Types of CVD surveillance programs Purposes Challenges and pitfalls
National or subnational any-cause
mortality registration
Tracking age and place of death allows
for basic demographic trend
projections and identiﬁcation of
highest mortality groups
Requires infrastructure
National or subnational CVD and other
cause-speciﬁc mortality registry or
verbal autopsy system
Complete counts of fatal cases;
tracking speciﬁc causes is more
informative regarding prevention
and control
Following sophisticated ICD rules is
difﬁcult and cause misclassiﬁcation
is common
Causes of unwitnessed sudden deaths
are difﬁcult to identify
Hospital-based and clinic-based event
registration
Allows tracking of temporal trends in
acute cases, tracking the number of
patients under treatment, and
planning hospital and clinic
capacity needs
Out-of-hospital events and out-of-clinic
cases are missed
Spectrum bias may lead to biased
estimates of total case fatality and
severity
National risk factor and prevalence
surveys
Necessary for quantifying risk factor
exposure levels and monitoring
effects of prevention programs
Self-reported measures (e.g., in
telephone surveys) are economical
but sometimes unreliable
Population-based cohort studies Overcomes the limitations of
ecological analysis by linking risk
factors and outcomes at the
individual level
Selection bias; observations may not
be generalizable to the general
population
National or subnational capture of all
fatal and nonfatal CVD cases
Complete counts of fatal and nonfatal
cases, captures full spectrum of
case fatality and severity
If subnational, may not be
generalizable
Active surveillance for cases occurring
in the community is resource
intensive and requires extensive
infrastructure and training
Individual-level linkage of outpatient
characteristics and risk factors,
inpatient events, and cause-of-
death registries
Complete counts of fatal and nonfatal
cases, ability to quantify upstream
risk factors, downstream events
and deaths at the level of the
individual, integrated with
monitoring of clinical practice and
quality of care, allows monitoring
effects of prevention and control
policies
Use of coded data leading to
misclassiﬁcation bias
Need for propensity score
adjustment
Electronic medical record keeping is an
advantage and not universally
available
CVD, cardiovascular disease; ICD, International Classiﬁcation of Diseases.
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8to track in the community, such as atrial ﬁbrillation and stable
coronary artery disease. New methods will be needed to
integrate multiple data sources, correct bias, and calculate
uncertainty. These efforts will go a long way to assuring that
cardiovascular surveillance efforts remain timely and policy-
relevant well into this new century.
1990-2010 GLOBAL CVD ATLAS: METHODS
The Global Burden of Diseases, Injuries, and Risk
Factors 2010 Study (GBD 2010)
The Global Burden of Diseases, Injuries, and Risk Factors
2010 Study (GBD 2010) used standardized methods to
estimate the burden of fatal and nonfatal CVDs and
noncardiovascular disease in the years 1990 and 2010.The GBD included 187 countries and 291 diseases and
injuries, including 9 distinct major cardiovascular con-
ditions as well as a combined category for other minor,
less common cardiovascular and circulatory conditions.
GBD 2010 Study methods have been reported in detail
elsewhere for the overall study and for major CVDs
[1e3,10]. The core summary measurement of population
health in the GBD 2010 Study was DALYs in the years
1990 and 2010. DALYs represent the “health gap” be-
tween a population’s actual health and an ideal standard.
DALYs are composed of years of life lost (YLL) to pre-
mature deaths and years lived with nonfatal disease
disability (YLD). In order to capture the combined fatal
and nonfatal burden of CVDs around the world, the
global CVD atlas reports DALYs.GLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16
FIGURE 7. Last year of vital registration ([VR] systematic registration of all births and deaths in the population) by
country, from 1980-2008.
gATLASjAbsolute numbers of DALYs lost and DALYs per
100,000 are the main outcomes reported in the tables and
ﬁgures of the global CVD atlas. Absolute numbers of
DALYs reﬂect the magnitude of burden, that is, lives and
life years lost due to CVD deaths, and the number of
chronic CVD survivors. Absolute numbers of DALYs are
important for health-system planners who need to provide
the health system with the capacity to care for CVD vic-
tims, assess economic and social impact, or compare the
urgency of CVD control priorities with priorities for con-
trolling non-CVD diseases. Because population size differs
among countries and changes over time in the same
country, we allow comparisons among countries and over
time by reporting DALYs per 100,000 people in atlas maps.
Age-standardized DALYs per 100,000 are reported in the
atlas text in selected instances in order to evaluate changes
in CVD burden over time in a region or country once both
the impacts of aging and population growth have been
removed. For those speciﬁc estimates, age standardization
was performed using the direct method and the World
Health Organization standard world population.
The GBD 2010 Study estimated mortality and burden
of disease for 187 countries nested within 21 world re-
gions. The 21 regions were in turn nested within 7 “super
regions.” Regions and super regions almost always con-
sisted of geographically contiguous countries, though
countries were also grouped into regions based on epide-
miologic characteristics (e.g., relative proportion ofGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16communicable/maternal and noncommunicable disease
mortality). Based on the availability of CVD epidemiology
data, 12 world regions were used for the global CVD atlas.
Atlas regions generally followed the geographical structure
of the GBD 2010 Study, but in some cases, GBD regions
were collapsed into a super region (e.g., Sub-Saharan Af-
rica), and in other cases, a super region was split into its
component GBD regions (splitting of High Income into
North America, Western Europe, Asia Paciﬁc High Income,
and Australasia; Fig. 8, Table 2).
Deﬁning CVDs
Ten major CVD cause categories were deﬁned based on In-
ternational Classiﬁcation of Disease (ICD) classiﬁcations:
stroke, ischemic heart disease, cardiomyopathy, rheumatic
heart disease, hypertensive heart disease, endocarditis, atrial
ﬁbrillation, aortic aneurysm, peripheral arterial disease, and
“other cardiovascular and circulatory.” The last “other” cate-
gory included cardiopulmonary disease (ICD-10 I27, I28),
non-rheumatic valvular disease (I34, I35, I36, I37), disorders
of the arteries, capillaries, or veins (I72, I77, I78, I83, I84, I87,
I88, I89), venous embolism and thrombosis (I82), hypoten-
sion (I95), postprocedural disorders (I97), and cardiovascular
disorders in syphilis and other diseases (I98) . Because heart
failure is not deﬁned as an underlying cause of death in the
ICD, separate methods were developed in order to distribute
heart failure deaths and nonfatal disability to upstream CVDs
and other causes of heart failure.9
FIGURE 8. The world regions of the Global Cardiovascular Disease Atlas, based on the availability of CVD epide-
miology data. The atlas reports data for Eastern Europe and Central Asia in a single section.
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10Measuring fatal CVD
The GBD 2010 Study collected all available global mortality
data, including vital registration, sample registration, verbal
autopsy, burial and mortuary data, in-hospital death data, po-
lice reports, national census, and relevant surveys. Nonspeciﬁc
conditions reported as an underlying cause of death were
redistributed using expert consensus and statistical methods
[19]. Differences over time in international classiﬁcation
of disease systems were mapped to a uniform system. An
ensemble model (Cause of Death ensemble model, or
CODem) was used to estimate cause-speciﬁc mortality by age
and sex across all 187 countries in the GBD study using the
collectedmortality data and a large set of country-level, cause-
of-death-speciﬁc covariates.Out-of-sample validity testingwas
performed for each model, and uncertainty was determined
using 1,000 draws taken from the posterior distribution of
CODem.An algorithm (CODCorrect) adjusted these estimates
for consistency with global estimates of all-cause mortality.
Measuring nonfatal CVD
NonfatalCVDprevalencewas estimated fromdata gathered in
systematic reviews of epidemiologic data using a Bayesian
meta-regression method (DisMod-MR) [10]. Disability from
each case of CVD and other diseases or injuries was estimated
in a household survey of lay people in Bangladesh, Indonesia,
Peru, Tanzania, and the U.S.A., and an international Web-
based survey of health professionals [20]. Distribution of
disability severity (mild, moderate, or severe) was based on
either studies of speciﬁc CVDs that used a disease-speciﬁc
symptom scale (e.g., Rankin scale for stroke, New York
State Heart Association classiﬁcation for heart failure) or by
using the distribution of Short Form 15 quality-of-life scores
among patients living with CVDs that were measured in the
U.S. Medical Expenditure Panel Survey.Measuring the burden of CVD attributable to risk
factors
The Comparative Risk Assessment arm of the GBD 2010
Study estimated the burden of cardiovascular diseases
attributable to risk factors [21]. National and subnational risk
factor surveys were analyzed in order to estimate for each risk
factor a mean exposure. An optimal, minimum risk exposure
and relative risk per unit of risk factor exposurewere obtained
from the literature. Attributable burden was calculated using
the population attributable fraction method, assuming inde-
pendent effects from each risk factor. The main risk factor
clusters were tobacco consumption, alcohol consumption,
physiologic factors (high fasting plasma glucose, high total
cholesterol, high blood pressure, high body mass index), diet
(diet low in fruits, diet low in vegetables, diet low in whole
grains, diet low innuts and seeds, diet high in processedmeat,
diet high in sugar-sweetened beverages, diet low in ﬁber, diet
low in seafood omega-3 fatty acids, diet low in poly-
unsaturated fatty acids, diet high in trans fatty acids, diet high
in sodium), air pollution (ambient particulate matter pollu-
tion or household air pollution from solid fuels), and other
environmental risks (lead exposure).
Regional demographic and health system indicators
In order to place the global CVD atlas burden of disease
ﬁndings in context, demographic and health system in-
dicators were selected from a public-access World Bank
data Website for each country in an atlas region [22]. In-
dicator selection was based on consensus among the atlas
editors. Country-level mean life expectancy, proportion of
the population aged 65 years or older, proportion urban
population, physicians per 1,000 people, and nurses per
1,000 people were the indicators selected. Because country
indicators were not normally distributed, medians of in-
dicators among the countries in a region are reported.GLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 3-16
TABLE 2. Global Atlas of Cardiovascular Disease 1990-2010 regions and GBD 2010 super-regions, regions, and countries
Global CVD
Atlas Region
GBD Super
Region GBD Region Country
East Asia/Paciﬁc
East Asia Asia, East China
Korea, Democratic People’s
Republic of
Taiwan
Southeast Asia Asia, Southeast Cambodia
Indonesia
Lao People’s Democratic Republic
Malaysia
Maldives
Myanmar
Philippines
Sri Lanka
Thailand
Timor-Leste
Viet Nam
Oceania Fiji
Kiribati
Marshall Islands
Micronesia, Federated States of
Papua New Guinea
Samoa
Solomon Islands
Tonga
Vanuatu
Eastern Europe/
Central Asia
Central Europe Europe, Central Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Hungary
Macedonia, the Former Yugoslav
Republic of
Montenegro
Poland
Romania
Serbia
Slovakia
Slovenia
(Continued)
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TABLE 2 Continued
Global CVD
Atlas Region
GBD Super
Region GBD Region Country
Eastern Europe
and Central
Asia
Europe, Eastern Belarus
Estonia
Latvia
Lithuania
Moldova
Russian Federation
Ukraine
Asia, Central Albania
Armenia
Azerbaijan
Georgia
Kazakhstan
Kyrgyzstan
Mongolia
Tajikistan
Turkmenistan
Uzbekistan
High Income
Asia Paciﬁc, High
Income
Asia Paciﬁc, High
Income
Brunei Darussalam
Japan
Korea, Republic of
Singapore
Australasia Australasia Australia
New Zealand
Western Europe Europe, Western Andorra
Austria
Belgium
Cyprus
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Israel
Italy
Luxembourg
Malta
Netherlands
Norway
Portugal
Spain
(Continued)
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TABLE 2 Continued
Global CVD
Atlas Region
GBD Super
Region GBD Region Country
Sweden
Switzerland
United Kingdom
North America North America,
High Income
Canada
United States
Latin America
and
Caribbean
Note: these three
countries
were included
in the GBD
2010 High
Income
category
Latin America,
Southern
Argentina
Chile
Uruguay
Latin America/
Caribbean
Latin American
and
Caribbean
Caribbean Antigua and Barbuda
Bahamas
Barbados
Belize
Cuba
Dominica
Dominican Republic
Grenada
Guyana
Haiti
Jamaica
Saint Lucia
Saint Vincent and the Grenadines
Suriname
Trinidad and Tobago
Latin America,
Andean
Bolivia
Ecuador
Peru
Latin America,
Central
Colombia
Costa Rica
El Salvador
Guatemala
Honduras
Mexico
Nicaragua
Panama
Venezuela
Latin America,
Tropical
Brazil
Paraguay
(Continued)
gATLASj
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TABLE 2 Continued
Global CVD
Atlas Region
GBD Super
Region GBD Region Country
North Africa/
Middle
East
North Africa/
Middle East
North Africa/
Middle East
Algeria
Bahrain
Egypt
Iran, Islamic Republic of
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab Jamahiriya
Morocco
Occupied Palestinian Territory
Oman
Qatar
Saudi Arabia
Syrian Arab Republic
Tunisia
Turkey
United Arab Emirates
Yemen
South Asia
South Asia Asia, South Afghanistan
Bangladesh
Bhutan
India
Nepal
Pakistan
Sub-Saharan
Africa
Sub-Saharan
Africa
Sub-Saharan
Africa, Central
Angola
Central African Republic
Congo
Congo, the Democratic
Republic of the
Equatorial Guinea
Gabon
Sub-Saharan
Africa, East
Burundi
Comoros
Djibouti
Eritrea
Ethiopia
(Continued)
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TABLE 2 Continued
Global CVD
Atlas Region
GBD Super
Region GBD Region Country
Kenya
Madagascar
Malawi
Mauritius
Mozambique
Rwanda
Seychelles
Somalia
Sudan
Tanzania, United
Republic of
Uganda
Zambia
Sub-Saharan
Africa,
Southern
Botswana
Lesotho
Namibia
South Africa
Swaziland
Zimbabwe
Sub-Saharan
Africa, West
Benin
Burkina Faso
Cameroon
Cape Verde
Chad
Cote d’Ivoire
Gambia
Ghana
Guinea
Guinea-Bissau
Liberia
Mali
Mauritania
Niger
Nigeria
Sao Tome and Principe
Senegal
Sierra Leone
Togo
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